Table 1 Demographic characteristics at baseline
Placebo | IFN β-1a 22 μg SC tiw | IFN β-1a 44 μg SC tiw | |||||||
|---|---|---|---|---|---|---|---|---|---|
Number of active T2 lesions at 6 months | All (n = 187) | Number of active T2 lesions at 6 months | All (n = 189) | Number of active T2 lesions at 6 months | All (n = 184) | ||||
0 (n = 39) | ≥4 (n = 64) | 0 (n = 85) | ≥4 (n = 28) | 0 (n = 95) | ≥4 (n = 24) | ||||
Age, years, mean (SD) | 36.4 (7.3) | 33.4 (7.8) | 34.7 (7.5) | 35.6 (6.5) | 30.2 (7.3) | 34.8 (7.0) | 35.5 (8.0) | 33.0 (6.7) | 35.2 (7.9) |
Sex, female, n (%) | 31 (79) | 47 (73) | 141 (75) | 53 (62) | 21 (75) | 126 (67) | 63 (66) | 14 (58) | 122 (66) |
Race, white, n (%) | 38 (97) | 63 (98) | 184 (98) | 84 (99) | 28 (100) | 188 (99) | 94 (99) | 24 (100) | 182 (99) |
Time since MS onset, years, mean (SD) | 6.6 (5.4) | 5.3 (4.3) | 6.1 (4.8) | 7.9 (6.45) | 5.4 (4.3) | 7.7 (6.1) | 7.1 (5.6) | 7.4 (6.9) | 7.8 (6.3) |
Number of relapses in past 2 years, mean (SD) | 2.7 (0.8) | 3.3 (1.4) | 3.0 (1.3) | 2.9 (1.0) | 3.2 (1.2) | 3.0 (1.1) | 2.9 (1.0) | 3.5 (1.6) | 3.0 (1.1) |
EDSS score, median | 2.0 | 2.5 | 2.5 | 2.5 | 2.0 | 2.5 | 2.5 | 3.0 | 2.5 |